Search Results
Aug 04, 2026, 06:45 ET SOPHiA GENETICS Reports Second Quarter 2026 Results
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30, 2026.
More news about: SOPHiA GENETICS
Aug 04, 2026, 06:15 ET SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies
More news about: SOPHiA GENETICS
Aug 04, 2026, 06:15 ET SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies
More news about: SOPHiA GENETICS
Jul 21, 2026, 08:00 ET SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
BOSTON and ROLLE, Switzerland, July 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced it will release its financial results for the second quarter 2026 before U.S. markets
More news about: SOPHiA GENETICS
Jun 22, 2026, 08:25 ET SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting
2026ROLLE, Switzerland, June 22, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced that its 2026 Annual General Meeting of shareholders adopted all proposals on the
More news about: SOPHiA GENETICS
Jun 19, 2026, 08:00 ET SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares
BOSTON and ROLLE, Switzerland, June 19, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the closing of its previously announced underwritten public offering with total gross
More news about: SOPHiA GENETICS
Jun 16, 2026, 21:21 ET SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares
BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the pricing of its previously announced underwritten public offering of 10,526,000
More news about: SOPHiA GENETICS
Jun 16, 2026, 16:20 ET SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares
BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the commencement of a proposed underwritten public offering of its ordinary shares.
More news about: SOPHiA GENETICS
Jun 10, 2026, 08:00 ET SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting
BOSTON and ROLLE, Switzerland, June 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today confirmed, ahead of its 2026 Annual General Meeting (AGM) scheduled for June 18, 2026, the leadership
More news about: SOPHiA GENETICS
Jun 10, 2026, 08:00 ET SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting
BOSTON and ROLLE, Switzerland, June 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today confirmed, ahead of its 2026 Annual General Meeting (AGM) scheduled for June 18, 2026, the leadership
More news about: SOPHiA GENETICS
Jun 04, 2026, 08:00 ET SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center
SOPHiA GENETICS (NASDAQ: SOPH) today announced that the company has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to the formation
More news about: SOPHiA GENETICS
May 13, 2026, 05:00 ET Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
LONDON, May 13, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid
More news about: SOPHiA GENETICS
May 13, 2026, 05:00 ET Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
LONDON, May 13, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid
More news about: SOPHiA GENETICS
May 05, 2026, 06:45 ET SOPHiA GENETICS Reports First Quarter 2026 Results
BOSTON and ROLLE, Switzerland, May 5, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today reported financial results for the first quarter ended March 31, 2026.
More news about: SOPHiA GENETICS
Apr 21, 2026, 08:00 ET SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026
BOSTON and ROLLE, Switzerland, April 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the first quarter 2026 before U.S. markets
More news about: SOPHiA GENETICS
Apr 16, 2026, 08:00 ET Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026
SAN DIEGO and NEW YORK, April 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in
More news about: SOPHiA GENETICS
Apr 16, 2026, 08:00 ET Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026
SAN DIEGO and NEW YORK, April 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in
More news about: SOPHiA GENETICS
Mar 03, 2026, 06:45 ET SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results
BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025.
More news about: SOPHiA GENETICS
Feb 25, 2026, 08:00 ET SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference
BOSTON and ROLLE, Switzerland, Feb. 25, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced that leadership will present at TD Cowen's 46th Annual Health Care Conference
More news about: SOPHiA GENETICS
Feb 17, 2026, 08:00 ET SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026
BOSTON and ROLLE, Switzerland, Feb. 17, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the fourth quarter and full year 2025 before
More news about: SOPHiA GENETICS
Feb 10, 2026, 09:22 ET SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems
BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network.
More news about: SOPHiA GENETICS
Jan 12, 2026, 07:00 ET SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan
BOSTON and ROLLE, Switzerland, Jan. 12, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited financial results for the fourth quarter and full year 2025,
More news about: SOPHiA GENETICS
Jan 12, 2026, 07:00 ET SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan
BOSTON and ROLLE, Switzerland, Jan. 12, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited financial results for the fourth quarter and full year 2025,
More news about: SOPHiA GENETICS
Jan 12, 2026, 07:00 ET SOPHiA GENETICS verstrekt voorlopige financiële resultaten voor het vierde kwartaal en het volledige jaar 2025, geeft richtsnoeren voor 2026 en kondigt overgangsplan voor de directie aan
BOSTON en ROLLE, Zwitserland, 12 januari 2026 /PRNewswire/ -- SOPHIA GENETICS (Nasdaq: SOPH, een wereldleider in AI-gedreven precisiegeneeskunde, heeft vandaag voorlopige niet-gecontroleerde financiële resultaten voor het vierde kwartaal en
More news about: SOPHiA GENETICS
Jan 12, 2026, 07:00 ET SOPHiA GENETICS gibt vorläufige Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2025 bekannt, veröffentlicht Prognose für 2026 und kündigt Plan für Wechsel in der Geschäftsführung an
BOSTON und ROLLE, Schweiz, 12. Januar 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), ein Weltmarktführer im Bereich der KI-gestützten Präzisionsmedizin, hat heute vorläufige, ungeprüfte Finanzergebnisse für das vierte Quartal und das
More news about: SOPHiA GENETICS